keyword
MENU ▼
Read by QxMD icon Read
search

bevacizumab colon cancer

keyword
https://www.readbyqxmd.com/read/28415706/the-role-of-targeted-agents-in-the-adjuvant-treatment-of-colon-cancer-a-meta-analysis-of-randomized-phase-iii-studies-and-review
#1
Bum Jun Kim, Jae Ho Jeong, Jung Han Kim, Hyeong Su Kim, Hyun Joo Jang
There has been debate as to whether targeted agents have beneficial effect when added to adjuvant chemotherapy for patient with colon cancer. We conducted this meta-analysis to investigate the role of targeted agents in the adjuvant treatment of colon cancer. We searched PubMed, MEDLINE, EMBASE, and the Cochrane Library databases. We included phase III trials with the data of disease-free survival (DFS) and adverse events (AEs) of adjuvant treatment with targeted agents. From 5 eligible studies, a total of 9,991 patients with resected colon cancer were included in the meta-analysis of hazard ratio (HR) for 3-year DFS and odds ratio (OR) for grade 3 or higher AEs...
March 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28408243/erlotinib-and-bevacizumab-in-patients-with-advanced-non-small-cell-lung-cancer-and-activating-egfr-mutations-belief-an-international-multicentre-single-arm-phase-2-trial
#2
Rafael Rosell, Urania Dafni, Enriqueta Felip, Alessandra Curioni-Fontecedro, Oliver Gautschi, Solange Peters, Bartomeu Massutí, Ramon Palmero, Santiago Ponce Aix, Enric Carcereny, Martin Früh, Miklos Pless, Sanjay Popat, Athanasios Kotsakis, Sinead Cuffe, Paolo Bidoli, Adolfo Favaretto, Patrizia Froesch, Noemí Reguart, Javier Puente, Linda Coate, Fabrice Barlesi, Daniel Rauch, Michael Thomas, Carlos Camps, Jose Gómez-Codina, Margarita Majem, Rut Porta, Riyaz Shah, Emer Hanrahan, Roswitha Kammler, Barbara Ruepp, Manuela Rabaglio, Marie Kassapian, Niki Karachaliou, Rachel Tam, David S Shames, Miguel A Molina-Vila, Rolf A Stahel
BACKGROUND: The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation with another EGFR mutation in treatment-naive patients has been associated with a shorter progression-free survival to EGFR inhibition than in the absence of the T790M mutation. To test this hypothesis clinically, we developed a proof-of-concept study, in which patients with EGFR-mutant NSCLC were treated with the combination of erlotinib and bevacizumab, stratified by the presence of the pretreatment T790M mutation...
April 10, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28407110/prognostic-and-predictive-value-of-primary-tumour-side-in-patients-with-ras-wild-type-metastatic-colorectal-cancer-treated-with-chemotherapy-and-egfr-directed-antibodies-in-six-randomised-trials
#3
D Arnold, B Lueza, J-Y Douillard, M Peeters, H-J Lenz, A Venook, V Heinemann, E Van Cutsem, J-P Pignon, J Tabernero, A Cervantes, F Ciardiello
Background: There is increasing evidence that metastatic colorectal cancer (mCRC) is a genetically heterogeneous disease and that tumours arising from different sides of the colon (left versus right) have different clinical outcomes. Furthermore, previous analyses comparing the activity of different classes of targeted agents in patients with KRAS wild-type (wt) or RAS wt mCRC suggest that primary tumour location (side), might be both prognostic and predictive for clinical outcome. Methods: This retrospective analysis investigated the prognostic and predictive influence of the localisation of the primary tumour in patients with unresectable RAS wt mCRC included in six randomised trials (CRYSTAL, FIRE-3, CALGB 80405, PRIME, PEAK and 20050181), comparing chemotherapy plus EGFR antibody therapy (experimental arm) with chemotherapy or chemotherapy and bevacizumab (control arms)...
April 12, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28392022/reox-evaluation-of-the-efficacy-of-retreatment-with-an-oxaliplatin-containing-regimen-in-metastatic-colorectal-cancer-a-retrospective-single-center-study
#4
Talita Costa, Jose Nuñez, Tiago Felismino, Leonardo Boente, Celso Mello
BACKGROUND: Treatment of metastatic colorectal adenocarcinoma (mCRC) has evolved, and survival is over 30 months in contemporary trials. Nevertheless, there is a paucity of effective regimes after the first or second-line treatment. Thus, reexposure to previously used drugs has become a treatment strategy for some patients. We aimed to evaluate the efficacy of retreatment with an oxaliplatin-containing regimen in mCRC and correlate this with clinicopathologic features. PATIENTS AND METHODS: We retrospectively analyzed 83 patients with mCRC who underwent reexposure to oxaliplatin (REOX)...
March 16, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28315202/validation-of-bevacizumab-therapy-effect-on-colon-cancer-subtypes-by-using-whole-body-imaging-in-mice
#5
Ivan Vuletic, Kedi Zhou, Hui Li, Huichen Bai, Xiangxi Meng, Sihao Zhu, Yichen Ding, Jun Li, Hongfang Sun, Qiushi Ren
PURPOSE: Preclinical imaging offers a useful tool for monitoring cancer biological behavior and therapy in vivo without the necessity of animal surgery. The following paper describes our examination of tumor progress and anti-angiogenic therapy with Bevacizumab on colon cancer subtypes (SW480 and SW620) by using different non-invasive real-time in vivo imaging techniques. PROCEDURES: Color Doppler ultrasound imaging (CDUI) was used to observe the formation of new blood vessels; a homemade fluorescence reflectance imaging (FRI) apparatus was mainly used to test the difference in VEGFR2 expression between the tumor subtypes...
March 17, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28284171/molecular-subtypes-of-metastatic-colorectal-cancer-are-associated-with-patient-response-to-irinotecan-based-therapies
#6
M Del Rio, C Mollevi, F Bibeau, N Vie, J Selves, J-F Emile, P Roger, C Gongora, J Robert, N Tubiana-Mathieu, M Ychou, P Martineau
BACKGROUND: Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab. The aim of this study was to evaluate if recently identified molecular subtypes of colon cancer are associated with response of metastatic patients to first-line therapy. PATIENTS AND METHODS: We collected and analysed 143 samples of human colorectal tumours with complete clinical annotations, including the response to treatment...
March 8, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28280605/next-generation-sequencing-identifies-interactome-signatures-in-relapsed-and-refractory-metastatic-colorectal-cancer
#7
Benny Johnson, Laurence Cooke, Daruka Mahadevan
BACKGROUND: In the management of metastatic colorectal cancer (mCRC), KRAS, NRAS and BRAF mutational status individualizes therapeutic options and identify a cohort of patients (pts) with an aggressive clinical course. We hypothesized that relapsed and refractory mCRC pts develop unique mutational signatures that may guide therapy, predict for a response and highlight key signaling pathways important for clinical decision making. METHODS: Relapsed and refractory mCRC pts (N=32) were molecularly profiled utilizing commercially available next generation sequencing (NGS) platforms...
February 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28261339/primary-tumor-location-as-a-predictive-factor-for-first-line-bevacizumab-effectiveness-in-metastatic-colorectal-cancer-patients
#8
Wen-Zhuo He, Fang-Xin Liao, Chang Jiang, Peng-Fei Kong, Chen-Xi Yin, Qiong Yang, Hui-Juan Qiu, Bei Zhang, Liang-Ping Xia
Background: Published papers reported contradictory results about the correlation between bevacizumab effectiveness and primary tumor location of metastatic colorectal cancer (mCRC). Methods: 740 mCRC patients treated with chemotherapy (CT group) and 244 patients treated with bevacizumab plus chemotherapy as first-line setting (CT + B group) were included. Propensity score analyses were used for patients' stratification and matching. Kaplan-Meier curves with log-rank tests were used to detect different overall survival (OS)...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28174387/-a-case-of-heterochronic-ovarian-metastasis-from-sigmoid-colon-cancer-after-sigmoidectomy-treated-with-capeox-that-included-bevacizumab
#9
Reiko Ono, Norihito Ise, Hiroshi Yoshioka, Wataru Iwasaki, Kimihiko Sato, Makoto Niwa
The patient was a 41-year-old woman. When she was 39 years old, she had undergone laparoscopic high anterior resection for sigmoid colon cancer without adjuvant chemotherapy. Histologically, the surgical specimen was type 2, tub2, pT4a (SE), pN0, int, INF b, ly1, v1, and pStage II. Nine months after the operation, she suffered from abdominal fullness. Laborato- rydata showed elevation of tumor markers: the CEA level was 6.48 ng/mL, the CA19-9 level was 89.70 U/mL, and the CA125 level was 662 U/mL. Computed tomographyrevealed bilateral ovarian tumors and lung and peritoneal nodules with massive ascites...
January 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133309/-a-case-of-resection-of-para-aortic-lymph-node-recurrence-three-years-after-curative-surgery-for-ascending-colon-cancer
#10
Yujiro Nishizawa, Taishi Hata, Hidekazu Takahashi, Naotsugu Haraguchi, Junichi Nishimura, Chu Matsuda, Tsunekazu Mizushima, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori
A79 -year-old woman underwent right hemicolectomy and D3 dissection for ascending colon cancer. Pathologically, the tumor was diagnosed as moderately differentiated adenocarcinoma, pSS, ly1, v1, pPM0, pDM0, pRM0, pN1(3/19), M0, pStage III a. Adjuvant chemotherapy using UFT/UZEL was administered. One and a half years after surgery, PET-CT showed para-aortic lymph node swelling with high FDG uptake. Chemotherapy administration(capecitabine plus bevacizumab)was started and the lymph node swelling reduced. However, 1 year after chemotherapy, the node was swollen again...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133303/-a-case-of-laparoscopic-resection-of-a-lymph-node-recurrence-after-surgery-for-descending-colon-cancer
#11
Miho Okano, Masaki Okuyama, Masaya Nishino, Hiromitsu Hoshino, Junji Kawada, Yongkook Kim, Toshimasa Tsujinaka
The patient was an 81-year-old woman who underwent laparoscopic anterior resection for her descending colon cancer with final pathology results of tub2, pT3(SS), int, INFb, ly0, v1, EX(-), no lymph metastasis, and fStage II . She was followed up without adjuvant chemotherapy. Six months after the surgery, a CT scan revealed a tumor shadow 8mm in diameter near the clip fixed around the inferior mesenteric vein(IMV). After another 3 months, the tumor size increased to 11mm and it was diagnosed as a recurrence...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133259/-two-episodes-of-colostomy-associated-intestinal-perforation-during-chemotherapy-for-metastatic-rectal-cancer
#12
Hiroshi Tamura, Ayaka Otani, Mizuki Tsukui, Koji Toge, Takahiro Otani, Yuki Hirose, Yuta Morimoto, Kei Yoshino, Tomoki Kido, Kazuhiko Endo, Hitoshi Kameyama, Takashi Kobayashi, Toshifumi Wakai
A 77-year-old woman with rectal cancer and synchronous liver metastasis underwent a Hartmann operation with D3 lymph node dissection in June 2014. mFOLFOX6 plus bevacizumab(bev)was then administered to treat the liver metastasis.In February 2015, multiple liver metastases were detected and the regimen was changed to FOLFIRI plus bev.After 3 courses, peritonitis due to intestinal perforation around the descending colostomy occurred, and an emergency operation(partial resection of the descending colon and transverse colostomy)was performed...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133248/-a-case-of-long-term-survival-after-repeated-peritoneal-recurrences-of-perforated-sigmoid-colon-cancer-treated-with-systemic-chemotherapy-and-r0-resection-of-peritoneal-tumors
#13
Takaoki Watanabe, Takashi Kobayashi, Atsuhiro Wakai, Ryoma Yagi, Kana Tanaka, Kohei Miura, Yosuke Tajima, Masayuki Nagahashi, Yoshifumi Shimada, Jun Sakata, Hitoshi Kameyama, Takashi Kobayashi, Toshifumi Wakai
We report here a case of long-term survival with repeated peritoneal recurrences after resection of perforated sigmoid colon cancer. A 65-year-old man presented with diarrhea and abdominal pain. Computed tomography(CT)revealed diffuse peritonitis caused by perforated sigmoid colon cancer. We performed sigmoidectomy with D2 lymphadenectomy and descending colostomy. Postoperatively, S-1 was administered for 12 months as adjuvant chemotherapy. CT showed peritoneal nodules 56 months after the surgery. After 10 courses of mFOLFOX6 plus bevacizumab, the tumors decreased in size (reduction rate of 34...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133141/-a-case-of-aortoesophageal-fistula-rupture-due-to-descending-thoracic-aortic-dissection-with-recurrent-colon-cancer-during-chemotherapy-containing-bevacizumab
#14
Takamaru Koda, Junichi Koike, Hiroshi Masuhara, Akiharu Kurihara, Hiroyuki Shiokawa, Mitsunori Ushigome, Tomoaki Kaneko, Takayuki Suzuki, Yuko Sawaguchi, Tomoyuki Katayanagi, Takerou Fujii, Yoshinori Watanabe, Kimihiko Funahashi, Hideaki Shimada, Hironori Kaneko
We report a case of aortoesophageal fistula rupture during the course of chemotherapy following colon cancer resection. The patient was a 77-year-old woman. Following recurrence of cancer of the sigmoid colon, the patient received a course of XELOX plus bevacizumab(Bmab)to treat peritoneal dissemination and lung metastases. She was brought by ambulance to our hospital's emergency department 55 days after the last dose of Bmab, with a chief complaint of hematemesis. Hematolo- gy results showed severe anemia with a hemoglobin level of 4...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133116/-two-cases-of-systemic-steroid-therapy-for-hyperbilirubinemia-after-right-hepatic-lobectomy-of-liver-metastasis-from-colorectal-cancer
#15
Keigo Yasumasa, Yoshikazu Morimoto, Nobutaka Hatanaka, Hitoshi Mizuno, Teruo Iwasaki, Takafumi Hirao, Hiroshi Noro, Kenji Sakai, Hideki Osawa, Yoshio Yamasaki
We report 2 cases of systemic steroid therapy for hyperbilirubinemia after right hepatic lobectomy for liver metastases from colorectal cancer.One of the patients was a 65-year-old man, diagnosed with transverse colon cancer with multiple liver metastases.After surgery for the primary lesion and chemotherapy(FOLFOX plus bevacizumab, FOLFIRI plus panitumumab), he underwent right hepatic lobectomy for the liver metastasis.His preoperative ICG 15 min was 8%.Conjugated hyperbilirubinemia without biliary stenosis occurred after the hepatectomy...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133113/-resection-of-paraaortic-lymph-node-recurrence-wherein-complete-response-to-bevacizumab-was-observed-after-surgery-for-sigmoid-colon-cancer
#16
Hideaki Ganno, Machiko Kawaguchi, Yuya Umebayashi, Syouta Aoyama, Hirofumi Sugita, Takeharu Noguchi, Hidetoshi Amagasa, Kenichiro Imai, Katsunori Ami, Akira Fukuda, Nobuhiko Aoki, Masayuki Ando, Shikofumi Tei
We report a case of resection of a paraaortic lymph node recurrence, wherein complete response to bevacizumab was observed. Our patient was a 50-year-old woman who had a paraaortic lymph node recurrence during adjuvant chemotherapy with FOLFOX 6 months after surgery for sigmoid colon cancer. She was treated with chemotherapy consisting of FOLFOX plus bevacizumab/FOLFIRI plus bevacizumab, which suppressed progression of the periaortic lymph node recurrence. She underwent surgery for the paraaortic lymph node recurrence, and the pathologic result was complete response...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133111/-unresectable-stage-iv-sigmoid-colon-cancer-with-extended-resection-for-primary-tumor-a-case-report
#17
Yuta Kimura, Nobuaki Suzuki, Shinobu Tomochika, Yuka Inoue, Hironori Tanaka, Yoshihiro Tokuhisa, Michihisa Iida, Kazuhiko Sakamoto, Shigeru Takeda, Tomio Ueno, Shigeru Yamamoto, Shigefumi Yoshino, Shoichi Hazama, Hiroaki Nagano
A 65-year-old woman who was diagnosed with unresectable Stage IV sigmoid colon cancer underwent transverse colostomy with double orifices. Although KRAS gene mutation was observed, we could not administer bevacizumab because of the risk of bleeding from the primary tumor and peritumoral abscess. We started bi-weekly XELOX therapy but bloody bowel discharge continued. We planned extended resection of the primary tumor in order to control the bleeding and perforation. Sigmoidectomy, partial resection of the left ureter and small intestine, partial hysterectomy, bilateral salpingo-oophorectomy, and umbilical tumor resection were performed and the patient was discharged on the 10th day after surgery...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28105361/computed-tomograpy-evaluation-of-morphological-changes-clinical-response-and-survival-in-colorectal-cancer-liver-metastasis-treated-by-regorafenib-a-case-report
#18
Nobuhisa Matsuhashi, Takao Takahashi, Junko Kato, Toshiyuki Tanahashi, Satoshi Matsui, Yoshiyuki Sasaki, Hisashi Imai, Yoshihiro Tanaka, Naoki Okumura, Kazuya Yamaguchi, Manabu Futamura, Shinji Osada, Kazuhiro Yoshida
Pathological response to preoperative chemotherapy was recently found to be correlated with improved survival and has been proposed as a new outcome end-point following resection of liver metastases from colorectal cancer (CRC). It was demonstrated that, particularly after therapy with bevacizumab, CRC liver metastases decreased in size and underwent distinct morphological changes on computed tomography (CT). However, morphological changes in response to treatment with regorafenib have not yet been reported...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28105235/impact-of-chemotherapy-on-eosinophilia-associated-advanced-rectal-cancer-a-case-report-and-review-of-the-literature
#19
Maki Inoue, Jun Kadono, Hiroshi Sugita, Toshihiro Nakazono, Shunsuke Motoi, Iwao Kitazono, Yuko Goto, Yoshihiko Fukukura, Makoto Yoshimitsu, Takaharu Misaka, Yutaka Imoto
The present study reports a case of eosinophilia-associated rectal cancer that was successfully stabilized using chemotherapy, and reviews the mechanisms of eosinophilia and the importance of chemotherapy. A 65-year-old man, who had previously been diagnosed with suspected rectal cancer, presented with the chief complaint of melena. Eosinophilia, abnormal blood coagulation, and elevated carcinoembryonic antigen and carbohydrate antigen 19-9 tumor marker levels were observed, and the patient was subsequently diagnosed with advanced rectal cancer accompanied by multiple lymph node metastases that extended from the para-aortic lymph nodes to the left axillary lymph nodes...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28050146/personalized-oncogenomics-in-the-management-of-gastrointestinal-carcinomas-early-experiences-from-a-pilot-study
#20
B S Sheffield, B Tessier-Cloutier, H Li-Chang, Y Shen, E Pleasance, K Kasaian, Y Li, S J M Jones, H J Lim, D J Renouf, D G Huntsman, S Yip, J Laskin, M Marra, D F Schaeffer
BACKGROUND: Gastrointestinal carcinomas are genomically complex cancers that are lethal in the metastatic setting. Whole-genome and transcriptome sequencing allow for the simultaneous characterization of multiple oncogenic pathways. METHODS: We report 3 cases of metastatic gastrointestinal carcinoma in patients enrolled in the Personalized Onco-Genomics program at the BC Cancer Agency. Real-time genomic profiling was combined with clinical expertise to diagnose a carcinoma of unknown primary, to explore treatment response to bevacizumab in a colorectal cancer, and to characterize an appendiceal adenocarcinoma...
December 2016: Current Oncology
keyword
keyword
115852
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"